Affiliations: Clinical Genetics Laboratory, Yijishan Hospital of
Wannan Medical College, Wuhu, Anhui, China | Department of Oncology, Yijishan Hospital of Wannan
Medical College, Wuhu, Anhui, China | Department of Urology, Yijishan Hospital
of Wannan Medical College, Wuhu, Anhui, China | Department of Urology, North Hospital, CHU of
Saint-Etienne, Saint-Etienne, France
Abstract: PURPOSE: The objective of this study is to determine whether or not
plasma cfDNA levels can predict efficacy of sorafenib in patient with
metastatic cRCC. MATERIALS AND METHODS: Plasma cfDNA levels were quantified by
quantitative real-time PCR at six different time-points (before treatment, 4
weeks, 8 weeks, 12 weeks, 16 weeks, and 24 weeks) in 18 metastatic cRCC
patients receiving sorafenib, as assessed by CT examination according to RECIST
1.1. RESULTS: A significantly lower plasma cfDNA level, measured from 8
weeks to 24 weeks, was found in patients with remission or stable disease than
in those with progression. Higher levels in plasma cfDNA levels during the
course of treatment indicated poor outcome. For predicting progression, a
sensitivity of 66.7% was achieved at 100% specificity using cfDNA levels at 8
weeks. CONCLUSIONS: Monitoring of plasma cfDNA levels during the course of
sorafenib therapy could identify metastatic cRCC patients who are likely to
exhibit a poor response at an early stage.
